Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16512738 | 1.00 | HCRTR1 (0.49) | HCRTR1LMNAGAAMEN1KMT2A | |
| SCHEMBL17863660 | 1.00 | HCRTR1 (0.49) | HCRTR1LMNAGAAMEN1KMT2A | |
| SCHEMBL20747142 | 1.00 | HCRTR1 (0.49) | HCRTR1LMNAGAAMEN1KMT2A | |
| SCHEMBL16486620 | 1.00 | HCRTR1 (0.49) | HCRTR1LMNAGAAMEN1KMT2A | |
| SCHEMBL17863662 | 0.85 | HCRTR1 (0.50) | HCRTR1LMNAGAATAS1R3TAS1R1 | |
| SCHEMBL16486932 | 0.85 | HCRTR1 (0.50) | HCRTR1LMNAGAATAS1R3TAS1R1 | |
| SCHEMBL16512784 | 0.85 | HCRTR1 (0.50) | HCRTR1LMNAGAATAS1R3TAS1R1 | |
| SCHEMBL17598752 | 0.83 | HCRTR1 (0.51) | HCRTR1LMNAGAATAS1R3TAS1R1 | |
| SCHEMBL16486890 | 0.82 | HCRTR1 (0.53) | HCRTR1LMNAGAATAS1R3TAS1R1 | |
| SCHEMBL20747118 | 0.82 | HCRTR1 (0.53) | HCRTR1LMNAGAATAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207985-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| EP-3033330-B1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20160176806-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| EP-3033330-A2 | NOVEL COMPOUNDS | Syngenta Participations AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022265-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176806-A1 | NOVEL COMPOUNDS | SGMS1, DDT, CYP1B1 | HCRTR1 230/4885LMNA 2782/4885GAA 626/4885 |
| US-10207985-B2 | Compounds | CYP1B1, DDT, CYP1A1 | HCRTR1 233/4885LMNA 1800/4885GAA 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.